Matched patients
| TNFi Combo vs TNFi Mono | Tofa Combo vs Tofa Mono | TNFi Combo vs Tofa Mono | |||
|---|---|---|---|---|---|
| 2nd line* (n=1130) | 3rd line (n=1044) | 4th line (n=680) | 3rd & 4th line (n=130) | 3rd and 4th line (n=186) | |
| LDA OR [95% CI] | 1.4 [1.1–1.8] | 1.1 [0.9–1.5] | 0.7 [0.5–1.0] | 1.2 [0.5–2.5] | 1.0 [0.4–1.8] |
| mACR20 OR [95% CI] | 1.6 [1.2–2.1] | 1.2 [0.9–1.5] | 1.2 [0.8–1.8] | 0.6 [0.3–1.6] | 0.9 [0.5–1.8] |
| ΔCDAI meanΔ [95% CI] | −2.0 [−3.4–0.6] | −0.9 [−2.5–0.6] | −2.1 [−4.1–0.1] | 0.2 [−4.8–5.2] | −1.6 [−4.8–1.7] |
*2nd line was defined as prior use of at least one cDMARD and no prior use of any biologic.